* DBV TECHNOLOGIES *
2002 - IDF
Boulogne Billancourt
(near Paris)
www.dbv-technologies.com Discovery, Diagnostics, Immunotherapy
Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest
Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT)
Clients: Pharmaceutical industry, Food industry, Cosmetics
nathalie.donne@dbv-technologies.com
Age: 9 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up (speciality pharma company) |
Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics]
Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, Sofinnova Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest | Turnover (M€) : 0.16 (2009), 0.11 (2008), 0.25 (2006)
Total funding (M€) : 19.3
Last funding (M€) : 6.0
Focus : Allergy
Position : Trade
Company confirm : 28-Apr-2011 |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .01 | 4th round-financing : 19.4 M€, including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and Alto Invest, as well as existing investors Sofinnova Partners and ALK Abello | RFIND | [8 years] |
| 2010 .09 | Patent : granted on Viaskin Allergen Delivery System, in USA | LEGAL | [8 years] |
| 2010 .03 | Nomination : Pierre-Henri Benhamou, new CEO (still CSO, research director), replacing Jean-François Biry | ORGN | [8 years] |
| 2009 .09 | Clinical trial (phase II) for Viaskin Peanut, a new drug for acute coronary syndrome (selected by NIH and US consortium) | CLIN | [7 years] |
| 2009 .09 | Licensing-out of milk allergy test to Laboratoires Bioprojet for France | LICOUT | [7 years] |
| 2009 .01 | 3rd round-financing : 6 M€, by Sofinnova Partners, ALK-Abello (Pharma company) | RFINC | [6 years] |
| 2007 .11 | Licensing-out of milk allergy test to Numico (today Danone) | LICOUT | [5 years] |
| 2006 .01 | 2nd round-financing : 12.3 M€, by Sofinnova Partners and Apax Partners | RFINB | [3 years] |
| 2003 .00 | 1st round-financing : 1.0 M€, by Cap Décisif and Créagro | RFINA | [0 year] |
| 2002 .11 | Company founded by Pierre-Henri Benhamou and Bertrand Dupont, with funding from ANVAR, based on new technology led by Prof. Christophe Dupont (AP-HP, Cochin Hospital) | ORGF | [0 year] | Actualisation / Updating: 28-Apr-2011 |
|
